NO20053537L - Preparater og fremgangsmater for forebyggelse og kontroll av insulinindusert hypoglycemi. - Google Patents

Preparater og fremgangsmater for forebyggelse og kontroll av insulinindusert hypoglycemi.

Info

Publication number: NO20053537L
Authority: NO; Norway
Prior art keywords: insulin; control; preparations; prevention; methods
Prior art date: 2002-12-27

Application number

NO20053537A

Other languages

English (en)

Norwegian (no)

Inventor

Daniel Trevor Green

Robert R Henry

Original Assignee

Diobex Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-27

Filing date

2005-07-19

Publication date

2005-08-26

2005-07-19 Application filed by Diobex Inc filed Critical Diobex Inc

2005-08-26 Publication of NO20053537L publication Critical patent/NO20053537L/no

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 6
102000004877 Insulin Human genes 0.000 title abstract 3
108090001061 Insulin Proteins 0.000 title abstract 3
229940125396 insulin Drugs 0.000 title abstract 3
208000013016 Hypoglycemia Diseases 0.000 title abstract 2
230000002218 hypoglycaemic effect Effects 0.000 title abstract 2
238000000034 method Methods 0.000 title 1
238000002360 preparation method Methods 0.000 title 1
230000002265 prevention Effects 0.000 title 1
102000051325 Glucagon Human genes 0.000 abstract 1
108060003199 Glucagon Proteins 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
229960004666 glucagon Drugs 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Infusion, Injection, And Reservoir Apparatuses (AREA)

NO20053537A 2002-12-27 2005-07-19 Preparater og fremgangsmater for forebyggelse og kontroll av insulinindusert hypoglycemi. NO20053537L (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US43673502P	2002-12-27	2002-12-27
US45497203P	2003-03-14	2003-03-14
US47034603P	2003-05-13	2003-05-13
PCT/US2003/041103 WO2004060387A1 (fr)	2002-12-27	2003-12-23	Compositions et procedes de prevention et reduction de l'hypoglycemie induite par l'insuline

Publications (1)

Publication Number	Publication Date
NO20053537L true NO20053537L (no)	2005-08-26

Family

ID=32719167

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20053537A NO20053537L (no)	2002-12-27	2005-07-19	Preparater og fremgangsmater for forebyggelse og kontroll av insulinindusert hypoglycemi.

Country Status (11)

Country	Link
US (2)	US7314859B2 (fr)
EP (1)	EP1578437A4 (fr)
JP (1)	JP2006514990A (fr)
KR (1)	KR20050086948A (fr)
CN (1)	CN1732012A (fr)
AU (1)	AU2003303634B2 (fr)
CA (1)	CA2509755A1 (fr)
MX (1)	MXPA05006994A (fr)
NO (1)	NO20053537L (fr)
NZ (1)	NZ541365A (fr)
WO (1)	WO2004060387A1 (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2280020T3 (en)	1999-06-29	2016-05-02	Mannkind Corp	Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
CA2479751C (fr)	2002-03-20	2008-06-03	Trent Poole	Appareil d'inhalation
US8372804B2 (en) *	2007-10-24	2013-02-12	Mannkind Corporation	Delivery of active agents
US20080260838A1 (en) *	2003-08-01	2008-10-23	Mannkind Corporation	Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US7655618B2 (en)	2002-12-27	2010-02-02	Diobex, Inc.	Compositions and methods for the prevention and control of insulin-induced hypoglycemia
WO2004060387A1 (fr)	2002-12-27	2004-07-22	Diobex, Inc.	Compositions et procedes de prevention et reduction de l'hypoglycemie induite par l'insuline
AU2004296821B2 (en) *	2003-12-05	2011-05-12	Carefusion 303, Inc.	Patient-controlled analgesia with patient monitoring system
KR20070029276A (ko) *	2004-06-29	2007-03-13	디오벡스, 인코포레이티드	인슐린으로 인한 저혈당증을 예방하고 조절하기 위한조성물 및 방법
CA2575692C (fr)	2004-08-20	2014-10-14	Mannkind Corporation	Catalyse de la synthese de dicetopiperazine
DK1791542T3 (en)	2004-08-23	2015-06-15	Mannkind Corp	Diketopiperazinsalte for pharmaceutical delivery
US8975227B2 (en) *	2005-07-15	2015-03-10	Emisphere Technologies, Inc.	Intraoral dosage forms of glucagon
ES2640282T3 (es)	2005-09-14	2017-11-02	Mannkind Corporation	Método de formulación de fármacos basado en el aumento de la afinidad de superficies de micropartículas cristalinas para agentes activos
CN101534846B (zh) *	2005-11-07	2014-11-05	印第安纳大学研究及科技有限公司	显示生理学溶解性和稳定性的胰高血糖素类似物
EP1986679B1 (fr)	2006-02-22	2017-10-25	MannKind Corporation	Procédé pour améliorer les propriétés pharmaceutiques de microparticules comprenant de la dicétopipérazine et un agent actif
US8785396B2 (en)	2007-10-24	2014-07-22	Mannkind Corporation	Method and composition for treating migraines
US8986253B2 (en)	2008-01-25	2015-03-24	Tandem Diabetes Care, Inc.	Two chamber pumps and related methods
US9220456B2 (en)	2008-04-04	2015-12-29	Hygieia, Inc.	Systems, methods and devices for achieving glycemic balance
US10624577B2 (en)	2008-04-04	2020-04-21	Hygieia, Inc.	Systems, devices, and methods for alleviating glucotoxicity and restoring pancreatic beta-cell function in advanced diabetes mellitus
ES2719305T3 (es)	2008-04-04	2019-07-09	Hygieia Inc	Sistema para optimizar un régimen de dosificación de insulina para un paciente
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
ES2929343T3 (es)	2008-06-13	2022-11-28	Mannkind Corp	Inhalador de polvo seco accionado por aspiración para la administración de fármacos
ES2904623T3 (es)	2008-06-20	2022-04-05	Mannkind Corp	Aparato interactivo para establecer un perfil en tiempo real de esfuerzos de inhalación
TWI494123B (zh) *	2008-08-11	2015-08-01	Mannkind Corp	超快起作用胰島素之用途
US8408421B2 (en)	2008-09-16	2013-04-02	Tandem Diabetes Care, Inc.	Flow regulating stopcocks and related methods
AU2009293019A1 (en)	2008-09-19	2010-03-25	Tandem Diabetes Care Inc.	Solute concentration measurement device and related methods
US8992464B2 (en)	2008-11-11	2015-03-31	Hygieia, Inc.	Apparatus and system for diabetes management
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
US9375529B2 (en)	2009-09-02	2016-06-28	Becton, Dickinson And Company	Extended use medical device
US9250106B2 (en)	2009-02-27	2016-02-02	Tandem Diabetes Care, Inc.	Methods and devices for determination of flow reservoir volume
US8573027B2 (en)	2009-02-27	2013-11-05	Tandem Diabetes Care, Inc.	Methods and devices for determination of flow reservoir volume
WO2010105094A1 (fr)	2009-03-11	2010-09-16	Mannkind Corporation	Appareil, système et procédé de mesure de résistance d'un inhalateur
MY157166A (en)	2009-06-12	2016-05-13	Mankind Corp	Diketopiperazine microparticles with defined specific surface areas
AU2010278894B2 (en)	2009-07-30	2014-01-30	Tandem Diabetes Care, Inc.	Infusion pump system with disposable cartridge having pressure venting and pressure feedback
CA2778698A1 (fr)	2009-11-03	2011-05-12	Mannkind Corporation	Appareil et methode de simulation d'efforts d'inhalation
EP2335755A1 (fr)	2009-12-17	2011-06-22	Sanofi-Aventis Deutschland GmbH	Dispositif et procédé pour la fourniture de deux ou plusieurs agents de médicament
KR20130018410A (ko)	2010-03-26	2013-02-21	노보 노르디스크 에이/에스	새로운 글루카곤 유사체
JP2013523620A (ja)	2010-03-26	2013-06-17	ノヴォノルディスクアー／エス	新規のグルカゴンアナログ
MX359281B (es)	2010-06-21	2018-09-21	Mannkind Corp	Sistema y metodos para suministrar un farmaco en polvo seco.
MX2013011175A (es)	2011-03-28	2013-11-01	Novo Nordisk As	Analogos de glucagon novedosos.
KR101940832B1 (ko)	2011-04-01	2019-01-21	맨카인드 코포레이션	의약 카트리지용 블리스터 패키지
RU2483748C2 (ru) *	2011-04-15	2013-06-10	Леонид Леонидович Клопотенко	Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде пластыря
RU2483749C2 (ru) *	2011-04-15	2013-06-10	Леонид Леонидович Клопотенко	Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде биопленки
UA113626C2 (xx) *	2011-06-02	2017-02-27		Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
WO2012174472A1 (fr)	2011-06-17	2012-12-20	Mannkind Corporation	Microparticules de dicétopipérazine de capacité élevée
EP2758426B1 (fr)	2011-09-23	2019-08-07	Novo Nordisk A/S	Nouveaux analogues de glucagon
IN2014DN03093A (fr)	2011-10-24	2015-05-15	Mannkind Corp
US9180242B2 (en)	2012-05-17	2015-11-10	Tandem Diabetes Care, Inc.	Methods and devices for multiple fluid transfer
BR112015000529B1 (pt)	2012-07-12	2022-01-11	Mannkind Corporation	Inalador de pó seco
WO2014066856A1 (fr)	2012-10-26	2014-05-01	Mannkind Corporation	Compositions et procédés de vaccin antigrippal inhalable
US10201656B2 (en)	2013-03-13	2019-02-12	Tandem Diabetes Care, Inc.	Simplified insulin pump for type II diabetics
US9173998B2 (en)	2013-03-14	2015-11-03	Tandem Diabetes Care, Inc.	System and method for detecting occlusions in an infusion pump
WO2014144895A1 (fr)	2013-03-15	2014-09-18	Mannkind Corporation	Compositions de dicétopipérazine microcristallines et procédés
US9492608B2 (en)	2013-03-15	2016-11-15	Tandem Diabetes Care, Inc.	Method and device utilizing insulin delivery protocols
MX362275B (es)	2013-04-18	2019-01-10	Novo Nordisk As	Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
AU2014290438B2 (en)	2013-07-18	2019-11-07	Mannkind Corporation	Heat-stable dry powder pharmaceutical compositions and methods
CA2920488C (fr)	2013-08-05	2022-04-26	Mannkind Corporation	Appareil d'insufflation et procedes
AU2014339922B2 (en) *	2013-10-24	2019-05-23	Trustees Of Boston University	Infusion system for preventing mischanneling of multiple medicaments
WO2015100439A1 (fr)	2013-12-26	2015-07-02	Tandem Diabetes Care, Inc.	Intégration de pompe à perfusion à un dispositif électronique distant
US9898585B2 (en)	2014-01-31	2018-02-20	Aseko, Inc.	Method and system for insulin management
US9486580B2 (en)	2014-01-31	2016-11-08	Aseko, Inc.	Insulin management
EP3107560A1 (fr)	2014-02-18	2016-12-28	Novo Nordisk A/S	Analogues du glucagon stables et leur utilisation dans le traitement de l'hypoglycémie
WO2015148905A1 (fr)	2014-03-28	2015-10-01	Mannkind Corporation	Utilisation d'insuline à action ultrarapide
EP3151852A1 (fr)	2014-06-04	2017-04-12	Novo Nordisk A/S	Co-agonistes de récepteur du glucagon/glp-1 à usage médical
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
US9892234B2 (en)	2014-10-27	2018-02-13	Aseko, Inc.	Subcutaneous outpatient management
US11081226B2 (en)	2014-10-27	2021-08-03	Aseko, Inc.	Method and controller for administering recommended insulin dosages to a patient
WO2017031440A1 (fr)	2015-08-20	2017-02-23	Aseko, Inc.	Conseiller de thérapie pour la gestion du diabète
JP7001584B2 (ja) *	2015-09-04	2022-01-19	ラティチュードファーマシューティカルズインコーポレイテッド	安定化されたグルカゴン溶液
US11013873B2 (en) *	2017-01-06	2021-05-25	HealthPartners Institite	Methods for treating patients with impaired awareness of hypoglycemia
JP7133229B2 (ja) *	2017-02-03	2022-09-08	ヴァンダービルトユニバーシティー	糖尿病を治療するためのシステム、組成物および方法
EP3900734A4 (fr) *	2018-12-21	2022-10-12	Hanmi Pharm. Co., Ltd.	Composition pharmaceutique contenant de l'insuline et du glucagon
KR102495891B1 (ko) *	2020-03-04	2023-02-06	이오플로우(주)	약액 제어 주입 디바이스
US20240216476A1 (en)	2021-04-27	2024-07-04	Aardvark Therapeutics, Inc.	Combination of bitter receptor agonist and gut-signaling compound
GB202109087D0 (en)	2021-06-24	2021-08-11	Norwegian Univ Sci & Tech Ntnu	Therapeutic methods and devices

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB748857A (en)	1952-12-16	1956-05-09	Nyegaard & Co As	Process for the making of adrenocorticotrophin (acth) preparations having a prolonged action from acth with high specific activity
GB766994A (en)	1953-11-13	1957-01-30	Novo Terapeutisk Labortorium A	Improved process in crystallization of insulin
GB766995A (en)	1953-11-14	1957-01-30	Novo Terapeutisk Labor As	Improvements in or relating to the production of insulin crystals
US2902408A (en) *	1957-09-12	1959-09-01	Organon	Suspensions of drugs destined for injection and process for the preparation thereof
GB831907A (en)	1957-09-12	1960-04-06	Organon Labor Ltd	Suspensions of drugs destined for injection and process for the preparation thereof
GB844434A (en)	1958-01-31	1960-08-10	Organon Nv	Insulin preparations and process for preparing same
US3897551A (en) *	1971-04-05	1975-07-29	Lilly Co Eli	Iodoglucagons and process for prolonging the biological activity of glucagon
US4003379A (en) *	1974-04-23	1977-01-18	Ellinwood Jr Everett H	Apparatus and method for implanted self-powered medication dispensing
US4498843A (en) *	1982-08-02	1985-02-12	Schneider Philip H	Insulin infusion pump
IT1170375B (it) *	1983-04-19	1987-06-03	Giuseppe Bombardieri	Apparecchio che infonde insulina o glucosio nel soggetto diabetico sulla base di determinazioni di concentrazioni di glucosio ottenute senza bisogno di prelievi del sangue del paziente
CA1196863A (fr) *	1983-06-08	1985-11-19	Mattheus F.A. Goosen	Composes d'insuline injectable a liberation lente
US4538616A (en) *	1983-07-25	1985-09-03	Robert Rogoff	Blood sugar level sensing and monitoring transducer
DK27885A (da) *	1985-01-22	1986-07-23	Novo Industri As	Fremstilling af peptider
AT391998B (de) *	1987-02-02	1990-12-27	Falko Dr Skrabal	Vorrichtung zur bestimmung der konzentration zumindest einer medizinischen substanz in lebenden organismen
US4879273A (en)	1987-05-22	1989-11-07	The Rockefeller University	Glucagon homologs and therapeutic use thereof
NL8701644A (nl)	1987-07-13	1989-02-01	Cordis Europ	Inrichting voor dosering in het lichaam van een vloeibaar materiaal.
US4943435A (en) *	1987-10-05	1990-07-24	Pharmetrix Corporation	Prolonged activity nicotine patch
US4839174A (en) *	1987-10-05	1989-06-13	Pharmetrix Corporation	Novel transdermal nicotine patch
US5101814A (en) *	1989-08-11	1992-04-07	Palti Yoram Prof	System for monitoring and controlling blood glucose
US5190041A (en) *	1989-08-11	1993-03-02	Palti Yoram Prof	System for monitoring and controlling blood glucose
US5234903A (en) *	1989-11-22	1993-08-10	Enzon, Inc.	Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
US5542935A (en) *	1989-12-22	1996-08-06	Imarx Pharmaceutical Corp.	Therapeutic delivery systems related applications
MY107937A (en) *	1990-02-13	1996-06-29	Takeda Chemical Industries Ltd	Prolonged release microcapsules.
JPH04218000A (ja)	1990-02-13	1992-08-07	Kirin Amgen Inc	修飾ポリペプチド
FR2663224B1 (fr) *	1990-06-14	1995-01-20	Applicationes Farmaceuticas Sa	Forme galenique parenterale.
US5612034A (en) *	1990-10-03	1997-03-18	Redcell, Inc.	Super-globuling for in vivo extended lifetimes
US5321008A (en) *	1991-01-10	1994-06-14	Amylin Pharmaceuticals, Inc.	Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5234906A (en) *	1991-01-10	1993-08-10	Amylin Pharmaceuticals, Inc.	Hyperglycemic compositions
US5527771A (en) *	1991-01-10	1996-06-18	Amylin Pharmaceuticals, Inc.	Methods and Compositions for treatment of diabetes mellitus, hypoglycemia & other conditions
US5656590A (en) *	1991-05-24	1997-08-12	Amylin Pharmaceuticals, Inc.	Treatment of anorexia and related states
US5814600A (en) *	1991-05-24	1998-09-29	Amylin Pharmaceuticals Inc.	Method and composition for treatment of insulin requiring mammals
CH683149A5 (fr) *	1991-07-22	1994-01-31	Debio Rech Pharma Sa	Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US6284727B1 (en) *	1993-04-07	2001-09-04	Scios, Inc.	Prolonged delivery of peptides
US6191105B1 (en) *	1993-05-10	2001-02-20	Protein Delivery, Inc.	Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5359030A (en)	1993-05-10	1994-10-25	Protein Delivery, Inc.	Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
SK31496A3 (en) *	1993-09-07	1998-06-03	Amylin Pharmaceuticals Inc	Use of amylin, amylin agonists and amylin antagonists for regulating gastrointestinal motility
US5512468A (en) *	1993-11-12	1996-04-30	Stratagene	Process of producing highly transformable bacterial cells and cells produced thereby
US5705483A (en) *	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en) *	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
NL9401886A (nl)	1994-05-27	1996-01-02	Dsm Nv	Samenstelling bestaande uit een dendrimeer en een in het dendrimeer opgesloten actieve stof, een werkwijze voor de bereiding van een dergelijke samenstelling en een werkwijze voor het vrijgeven van de actieve stof.
US5474552A (en) *	1994-06-27	1995-12-12	Cb-Carmel Biotechnology Ltd.	Implantable drug delivery pump
US5707641A (en)	1994-10-13	1998-01-13	Pharmaderm Research & Development Ltd.	Formulations comprising therapeutically-active proteins or polypeptides
WO1996028475A1 (fr)	1995-03-10	1996-09-19	Nakamura, Toshikazu	Facteur de croissance des hepatocytes modifie a l'aide de polyethylene glycol
US5869602A (en)	1995-03-17	1999-02-09	Novo Nordisk A/S	Peptide derivatives
IL114673A (en)	1995-07-19	2000-12-06	Hadasit Med Res Service	Pharmaceutical compositions containing protein for oral administration
US5849322A (en) *	1995-10-23	1998-12-15	Theratech, Inc.	Compositions and methods for buccal delivery of pharmaceutical agents
US5741211A (en) *	1995-10-26	1998-04-21	Medtronic, Inc.	System and method for continuous monitoring of diabetes-related blood constituents
CN1154726C (zh)	1995-12-27	2004-06-23	基因技术股份有限公司	具长半衰期的ob蛋白质衍生物
AU2549297A (en) *	1996-03-28	1997-10-17	Board Of Trustees Of The University Of Illinois, The	Materials and methods for making improved echogenic liposome compositions
IL118003A0 (en) *	1996-04-23	1996-08-04	Yeda Res & Dev	Novel vip fragments and pharmaceutical compositions comprising them
US5840733A (en) *	1996-07-01	1998-11-24	Redcell, Canada, Inc.	Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
IL128332A0 (en)	1996-08-30	2000-01-31	Novo Nordisk As	GLP-1 derivatives
JP4295831B2 (ja)	1997-01-15	2009-07-15	ポラリス・グループ	改変された腫瘍壊死因子
MY118835A (en) *	1997-04-18	2005-01-31	Ipsen Pharma Biotech	Sustained release compositions and the process for their preparation
US5869062A (en) *	1997-05-27	1999-02-09	Oliver; Benjamin	Skin treatment composition
US5919216A (en) *	1997-06-16	1999-07-06	Medtronic, Inc.	System and method for enhancement of glucose production by stimulation of pancreatic beta cells
US6093167A (en) *	1997-06-16	2000-07-25	Medtronic, Inc.	System for pancreatic stimulation and glucose measurement
US6437092B1 (en) *	1998-11-06	2002-08-20	Conjuchem, Inc.	Conjugates of opioids and endogenous carriers
AU1384199A (en) *	1997-11-07	1999-05-31	Chiron Corporation	Method for producing igf-1 sustained-release formulations
EP1056775B1 (fr)	1998-02-27	2010-04-28	Novo Nordisk A/S	Derives de gpl-1 et de l'extendine au profil d'action etendu
US6107489A (en) *	1998-03-17	2000-08-22	Conjuchem, Inc.	Extended lifetimes in vivo renin inhibitors
KR19990085365A (ko) *	1998-05-16	1999-12-06	허영섭	지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
RU2205188C2 (ru) *	1998-06-30	2003-05-27	Ново Нордиск А/С	Затравочные кристаллы для получения пептидов или протеинов
AU1574900A (en) *	1998-12-04	2000-06-26	Provalis (Uk) Limited	Pharmaceutical compositions containing insulin
US20020114829A1 (en) *	1998-12-18	2002-08-22	Hayat Onyuksel	Materials and methods for making improved liposome compositions
US6360888B1 (en) *	1999-02-25	2002-03-26	Minimed Inc.	Glucose sensor package system
US6261280B1 (en) *	1999-03-22	2001-07-17	Medtronic, Inc	Method of obtaining a measure of blood glucose
HK1039065B (en) *	1999-04-08	2004-04-16	Genentech, Inc.	Composition based on oppositely-charged polypeptides
US6319510B1 (en) *	1999-04-20	2001-11-20	Alayne Yates	Gum pad for delivery of medication to mucosal tissues
ATE252601T1 (de) *	1999-05-17	2003-11-15	Conjuchem Inc	Lang wirkende insulinotrope peptide
US6514500B1 (en) *	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
US6461331B1 (en) *	1999-05-21	2002-10-08	Minimed Inc.	Device and method for infusion of small molecule insulin mimetic materials
US20020026141A1 (en) *	1999-11-04	2002-02-28	Medtronic, Inc.	System for pancreatic stimulation and glucose measurement
US6540982B1 (en) *	2000-01-25	2003-04-01	Aeropharm Technology Incorporated	Medical aerosol formulation
JP2003524652A (ja) *	2000-02-29	2003-08-19	ツァン，ツィエ	改良された経皮薬剤パッチ
US6572542B1 (en) *	2000-03-03	2003-06-03	Medtronic, Inc.	System and method for monitoring and controlling the glycemic state of a patient
US6548049B1 (en)	2000-05-01	2003-04-15	Aeropharm Technology Incorporated	Medicinal aerosol formulation
US6565833B1 (en)	2000-05-01	2003-05-20	Aeropharm Technology Incorporated	Medicinal aerosol formulation
US7037889B2 (en)	2000-09-13	2006-05-02	Praecis Pharmaceuticals Inc.	Pharmaceutical compositions for sustained drug delivery
JP5170931B2 (ja)	2000-10-16	2013-03-27	中外製薬株式会社	Ｐｅｇ修飾エリスロポエチン
AU2002230509A1 (en)	2000-11-28	2002-06-11	Martin G. Baum	Devices and methods for treating low blood sugar levels
EP1355942B1 (fr)	2000-12-07	2008-08-27	Eli Lilly And Company	Proteines hybrides glp-1
US6656590B2 (en) *	2001-01-10	2003-12-02	Cabot Corporation	Coated barium titanate-based particles and process
WO2002056940A2 (fr) *	2001-01-22	2002-07-25	Integrated Sensing Systems, Inc.	Système de cathéter détecteur et procédé de fabrication
AU2003274601A1 (en) *	2002-11-18	2004-06-15	Pfizer Products Inc.	Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides
WO2004060387A1 (fr)	2002-12-27	2004-07-22	Diobex, Inc.	Compositions et procedes de prevention et reduction de l'hypoglycemie induite par l'insuline
US7806854B2 (en)	2005-05-13	2010-10-05	Trustees Of Boston University	Fully automated control system for type 1 diabetes

2003
- 2003-12-23 WO PCT/US2003/041103 patent/WO2004060387A1/fr not_active Ceased
- 2003-12-23 CA CA002509755A patent/CA2509755A1/fr not_active Abandoned
- 2003-12-23 JP JP2005508608A patent/JP2006514990A/ja active Pending
- 2003-12-23 US US10/540,803 patent/US7314859B2/en not_active Expired - Fee Related
- 2003-12-23 CN CNA2003801075753A patent/CN1732012A/zh active Pending
- 2003-12-23 AU AU2003303634A patent/AU2003303634B2/en not_active Ceased
- 2003-12-23 KR KR1020057012139A patent/KR20050086948A/ko not_active Ceased
- 2003-12-23 MX MXPA05006994A patent/MXPA05006994A/es unknown
- 2003-12-23 NZ NZ541365A patent/NZ541365A/en unknown
- 2003-12-23 EP EP03814932A patent/EP1578437A4/fr not_active Withdrawn
2005
- 2005-07-19 NO NO20053537A patent/NO20053537L/no not_active Application Discontinuation
2007
- 2007-12-21 US US11/963,584 patent/US7642232B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20060160722A1 (en)	2006-07-20
JP2006514990A (ja)	2006-05-18
MXPA05006994A (es)	2005-10-18
AU2003303634A1 (en)	2004-07-29
NZ541365A (en)	2009-09-25
US7642232B2 (en)	2010-01-05
WO2004060387A1 (fr)	2004-07-22
CA2509755A1 (fr)	2004-07-22
CN1732012A (zh)	2006-02-08
EP1578437A1 (fr)	2005-09-28
EP1578437A4 (fr)	2006-08-09
US7314859B2 (en)	2008-01-01
US20080096801A1 (en)	2008-04-24
AU2003303634B2 (en)	2009-10-01
KR20050086948A (ko)	2005-08-30

Publication	Publication Date	Title
NO20053537L (no)	2005-08-26	Preparater og fremgangsmater for forebyggelse og kontroll av insulinindusert hypoglycemi.
Heise et al.	2017	Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: a randomized, double‐blind, crossover trial
Heise et al.	2015	Faster‐acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart
MY145590A (en)	2012-02-29	Phenylacetamides and their use as glucokinase modulators
JP2003521528A5 (fr)	2009-06-25
NO20070174L (no)	2007-03-13	Preparater og fremgangsmater for forebyggelse og kontroll av insulindindusert hypoglykemi
NO20003051L (no)	2000-06-14	Metode for administrering av AspB28-humant insulin
MXPA05003346A (es)	2005-11-23	Control glicemico mejorado para prediabetes y/o diabetes tipo ii utilizando acido docosahexaenoico.
BRPI0410972C1 (pt)	2021-05-25	método para aumentar a vida de armazenagem de uma composição farmacêutica, composição farmacêutica, e, método para tratamento de hiperglicemia
EP2330092A3 (fr)	2012-07-25	Médicament comprenant steviol ou isosteviol pour le traitement du diabète non insulinodépendant, de l'hypertension et/ou du syndrome métabolique
BRPI0406499A (pt)	2005-12-06	Insulina de longa atuação para redução da morbidez e mortalidade cardiovascular em pacientes pré-diabéticos e pacientes com diabetes tipo 2
HUP0300325A2 (hu)	2003-07-28	A cukorbetegséggel járó szövődmény és neuropátia kezelésére szolgáló gyógyszerkészítmények és ezek alkalmazásai és előállításuk
BR0011891A (pt)	2002-03-05	Composto, composição farmacêutica, uso de um composto, métodos para tratamento de uma doença ou condição mediada pelo hpparso , para diminuir triglicerìdios em um paciente, para tratar a diabete do tipo 2, diminuir a resistência à insulina ou abaixar a pressão sanguìnea em um paciente, para diminuir os nìveis de fribogênio em um paciente, para diminuir o ldlc em um paciente e para mudar o tamanho da partìcula do ldl denso pequeno para denso normal em um paciente, e , uso de uma agonista hpparso
UA88440C2 (ru)	2009-10-26	ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β
NO20053041L (no)	2005-09-02	Behandling av diabetes.
WO2004050115A3 (fr)	2004-07-22	Polytherapie mettant en oeuvre des exendines et des thiazolidinediones
Einhorn et al.	2015	Patients achieving good glycemic control (HbA1c< 7%) experience a lower rate of hypoglycemia with insulin degludec than with insulin glargine: a meta-analysis of phase 3a trials
DK1482919T3 (da)	2007-07-30	Farmaceutisk sammensætning til blodsukkerkontrol hos patienter med type 2 diabetes
DE60222383D1 (de)	2007-10-25	Medikament zur verabreichung von amifostin und verwandten wirkstoffen
EA200600402A1 (ru)	2006-08-25	Клеточные стенки дрожжей для лечения или профилактики гипергликемии или для стабилизации уровня сахара в крови
WO2005117937A3 (fr)	2006-05-11	Alpha-1- acide glycoproteine pour le traitement des diabetes
BRPI0410761A (pt)	2006-06-27	uso de leucina, e, composição para administração entérica a pacientes
NO20061417L (no)	2006-03-28	Syreinneholdende oxaliplatinformuleringer
RU96115219A (ru)	1998-10-27	Способ лечения больных сахарным диабетом
DK1675611T3 (da)	2009-04-06	Terapeutiske anvendelser for C-peptid

Legal Events

Date	Code	Title	Description
2011-02-14	FC2A	Withdrawal, rejection or dismissal of laid open patent application